2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Christopher R. D’Angelo, MD, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Christopher R. D’Angelo, MD, an assistant professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.
The 5-drug ViPOR combination of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid) is being evaluated in a phase 1b/2 trial (NCT03223610) in patients with relapsed/refractory B-cell lymphoma.
Adding more agents to a traditional doublet regimen confers potential drawbacks, including the risk of significant toxicity, says D’Angelo. Moreover, when multiple agents are added to a single regimen, patients are left with less options should they relapse, D’Angelo explains. Additionally, some novel treatment strategies are utilizing oral agents, which are often dosed indefinitely or until a patient progresses or relapses, D’Angelo explains.
Time-limited combinations that are not associated with significant up-front toxicity and can prolong survival are intriguing, D’Angelo says. However, multiple-drug combinations that induce responses but do not prolong life may not be optimal for this patient population, concludes D’Angelo.
Related Content: